EGFR and glioblastoma: Second, according to the 2021 WHO CNS5, IDH wildtype diffuse astrocytic glioma (grade 2, 3) in adults with TERT promoter mutation, or EGFR gene amplification, or + 7/ − 10 chromosome copy number changes are now classified as GBM.